Blueprint Medicines Corp

Blueprint Medicines — Investor Presentation (September 2020)

18 slides from Blueprint Medicines's investor presentation, Sep 22, 2020

  1. Slide 1: Topline data for EXPLORER and PATHFINDER clinical trials in advanced systemic mastocytosis

    © 2020 Blueprint Medicines Corporation R.S., living with systemic mastocytosis Topline data for EXPLORER and PATHFINDER clinical trials in advanced systemic mastocytosis SEPTEMBER 22, 2020

  2. Slide 2: Forward-looking statements

    Forward-looking statements 2 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “aim,” “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “

  3. Slide 3: Blueprint Medicines call participants

    Blueprint Medicines call participants Introduction Kristin Hodous, Sr. Manager, Investor Relations Opening remarks Jeff Albers, Chief Executive Officer Review of topline EXPLORER and PATHFINDER data Andy Boral, MD, PhD, Chief Medical Officer Opportunity to deliver therapeutic value to patients with

  4. Slide 4: Top-line advanced SM data adds to increasing portfolio strength

    Top-line advanced SM data adds to increasing portfolio strength 1. Full prescribing information is available at www.GAVRETO.com. advSM, advanced systemic mastocytosis; ESMO, European Society of Medical Oncology; FDA, U.S. Food and Drug Administration; GIST, gastrointestinal stromal tumors; ISM, indo

  5. Slide 5: Top-line data

    Top-line EXPLORER and PATHFINDER data Andy Boral, MD, PhD, Chief Medical Officer

  6. Slide 6: Driven by KIT D816V, systemic mastocytosis is characterized by debilitating symptoms and organ damage

    Driven by KIT D816V, systemic mastocytosis is characterized by severely debilitating symptoms and organ damage Mild symptoms Non-Advanced SM Severe symptoms Indolent SM (ISM) • Some progression to advanced disease (4%)2 • Long-term morbidity, including life- threatening anaphylaxis, frequent GI upse

  7. Slide 7: Comprehensive development program designed to support avapritinib registration in advanced SM

    Comprehensive development program designed to support avapritinib registration in advanced systemic mastocytosis 7 mIWG, modified International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) response criteria. QD, once

  8. Slide 8: Planned avapritinib sNDA submission for advanced SM to include pooled data

    Planned avapritinib sNDA submission for advanced SM to include pooled data from the EXPLORER and PATHFINDER trials All topline data in this presentation are as of a data cutoff of May 27, 2020 for EXPLORER and a data cutoff of June 23, 2020 for PATHFINDER, with response assessments per central revie

  9. Slide 9: Consistently high ORRs and prolonged duration of response across trials

    Consistently high ORRs and prolonged duration of response across trials CR, complete remission; CRh, CR with partial hematologic recovery; CI, clinical improvement; mDOR, median duration of response; mOS, median overall survival; NE, not estimable; ORR, overall response rate; PR, partial remission.

  10. Slide 10: Response kinetics are similar, with deepening responses over time

    EXPLORER and PATHFINDER response kinetics are similar, with deepening responses over time with longer-term follow up PD, progressive disease; SD, stable disease. 10 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 0 10 20 30 40 50 60 70 80 90 100 P a t i e n t s ( % ) NE PD SD CI PR CRh CR 32 n =

  11. Slide 11: Consistent impact on objective measures of mast cell burden across trials

    Consistent impact on objective measures of mast cell burden across trials 11 -100 -80 -60 -40 -20 0 20 M a x i m u m P e r c e n t C h a n g e f r o m B a s e l i n e BLU-285-2202 BLU-285-2101 Study SERUM TRYPTASE -100 -80 -60 -40 -20 0 20 40 60 M a x i m u m P e r c e n t C h a n g e f r o m B a s

  12. Slide 12: Avapritinib demonstrated improved tolerability at 200 mg QD

    Avapritinib demonstrated improved tolerability at 200 mg QD 12 Treatment Emergent AEs ≥ 20%, All Grades* 200 mg n=81 (%) All doses N=148 (%) Peripheral Edema 39 ( 48.1) 65 ( 43.9) Periorbital Edema 32 ( 39.5) 81 ( 54.7) Thrombocytopenia 28 ( 34.6) 55 ( 37.2) Anemia 26 ( 32.1) 65 ( 43.9) Diarrhea 23

  13. Slide 13: Summary of top-line trial results

    Summary of top-line EXPLORER and PATHFINDER trial results 13 Consistently high IWG response rates across trials and at the proposed labeled 200 mg QD dose, with prolonged overall survival in EXPLORER Avapritinib was generally well-tolerated, with improved safety at 200 mg QD and with platelet manage

  14. Slide 14: Opportunity to deliver therapeutic value to patients with SM

    Opportunity to deliver therapeutic value to patients with SM Christy Rossi, Chief Commercial Officer

  15. Slide 15: Systemic mastocytosis is one disease driven by KIT D816V

    Systemic mastocytosis is one disease driven by KIT D816V 15 Advanced SM Non-advanced SM (Indolent and smoldering) Requirement for life-long chronic treatment Debilitating symptoms Significant organ damage Importance of time to response ~75,000 patients in major markets Patient numbers in major marke

  16. Slide 16: Significant initial target patient population with additional growth potential

    Significant initial target patient population with additional growth potential Major markets include US, EU5 and Japan. 1. Cohen S et al Br J Haematol (2014) 166(4):521-8 and World Bank Population estimates. 16 ~75,000 Patients in major markets ~1/3 Diagnosed Initial opportunity Growth opportunity E

  17. Slide 17: Avapritinib is the only clinically validated, highly potent inhibitor of KIT D816V

    Avapritinib is the only clinically validated, highly potent inhibitor of KIT D816V, the genetic driver of SM 1. Topline EXPLORER and PATHFINDER data reported in September 2020. 2. Data reported at AAAAI Annual Meeting in March 2020. Data cutoff: December 27, 2019. 17 REDUCE MAST CELL BURDEN IMPROVE

  18. Slide 18: Thank you

    Thank you Blueprint Medicines, AYVAKIT, GAVRETO and associated logos are trademarks of Blueprint Medicines Corporation.

Blueprint Medicines — Investor Presentation (September 2020) on 6ix